Paper Details

  1. Home
  2. Paper Details

Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4.

Author: AbadSoraya, AlbalateMarta, HernándezEduardo, López-GómezJuan M, MacíasNicolás, MillaMonica, MéridaEvangelina, VegaAlmudena, de SequeraPatricia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study investigated the efficacy and safety of a combination of ombitasvir/paritaprevir/ritonavir and dasabuvir, direct-acting antivirals (DAAs), for treating hepatitis C virus (HCV) infection in patients on hemodialysis. The study found that this DAA combination was well-tolerated and achieved high rates of sustained virological response (SVR) in both HCV monoinfected and HIV/HCV co-infected patients.
Paper Details　
Original Abstract of the Article :
Hepatitis C virus (HCV) infection is highly prevalent among patients on hemodialysis (HD) and is associated with poor prognosis. Treatment with interferon and ribavirin is poorly tolerated, and few data are available on the impact of new direct-acting antivirals (DAAs). This study was intended to an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000454819

データ提供：米国国立医学図書館（NLM）

A Breakthrough in Hepatitis C Treatment: DAAs for Patients on Hemodialysis

Hepatitis C virus (HCV) infection is a significant health concern, particularly among patients on hemodialysis (HD). Traditional treatment options using interferon and ribavirin have been poorly tolerated. This study aimed to evaluate the efficacy and safety of a combination of direct-acting antivirals (DAAs) in HCV-infected patients on HD. The researchers analyzed data from patients treated with a combination of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. The results demonstrated a high rate of sustained viral response, suggesting that DAAs offer a promising treatment option for HCV-infected patients on HD.

DAAs: A New Era of Treatment for Hepatitis C in Hemodialysis Patients

This study provides compelling evidence that DAAs offer a highly effective and well-tolerated treatment for HCV-infected patients on HD. This breakthrough represents a significant advancement in managing this challenging condition, potentially improving the quality of life and long-term health outcomes for these patients.

Navigating the Desert of Hepatitis C

The desert of hepatitis C can be a harsh and unforgiving landscape, particularly for those on HD. This study, like a beacon of hope in the desert, reveals a new path towards effective treatment, offering a chance for recovery and a brighter future.

Dr.Camel's Conclusion

This study offers a glimmer of hope for HCV-infected patients on HD, demonstrating the effectiveness and safety of DAA therapy. The high rate of sustained viral response suggests that DAAs offer a promising treatment option, potentially transforming the management of HCV in this patient population. This research signifies a significant advancement in the fight against hepatitis C, offering new hope for a healthier future.

Date :
  1. Date Completed 2017-12-25
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

28166520

DOI: Digital Object Identifier

10.1159/000454819

Related Literature

Article Analysis
・Side Effects of ombitasvir paritaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.